0001209191-22-035031.txt : 20220608
0001209191-22-035031.hdr.sgml : 20220608
20220608162441
ACCESSION NUMBER: 0001209191-22-035031
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220607
FILED AS OF DATE: 20220608
DATE AS OF CHANGE: 20220608
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Chen Hubert C
CENTRAL INDEX KEY: 0001622297
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38052
FILM NUMBER: 221003805
MAIL ADDRESS:
STREET 1: C/O PFENEX INC.
STREET 2: 10790 ROSELLE STREET
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Forte Biosciences, Inc.
CENTRAL INDEX KEY: 0001419041
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 261243872
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1124 W CARSON STREET
STREET 2: MRL BUILDING 3-320
CITY: TORRANCE
STATE: CA
ZIP: 90502
BUSINESS PHONE: (310) 618-6994
MAIL ADDRESS:
STREET 1: 1124 W CARSON STREET
STREET 2: MRL BUILDING 3-320
CITY: TORRANCE
STATE: CA
ZIP: 90502
FORMER COMPANY:
FORMER CONFORMED NAME: Tocagen Inc
DATE OF NAME CHANGE: 20071120
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-06-07
0
0001419041
Forte Biosciences, Inc.
FBRX
0001622297
Chen Hubert C
C/O FORTE BIOSCIENCES, INC.
3060 PEGASUS PARK DR., BLDG 6
DALLAS
TX
75247
0
1
0
0
See remarks
Stock Option (right to buy)
1.30
2022-06-07
4
A
0
250000
0.00
A
2032-06-07
Common Stock
250000
250000
D
Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2020 Inducement Equity Incentive Plan) through each applicable vesting date, twenty five percent (25%) of the shares subject to the option shall vest on the one year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the total shares subject to the option shall vest every month thereafter such that all shares shall be fully vested on the four year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean June 7, 2022.
President and Chief Scientific Officer
/s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact
2022-06-08